Ian Nicholson is the founder of F2G. F2G has raised $61M in total funding. Latest round: Series B. Based in Manchester, United Kingdom.
Ian Nicholson is the CEO of F2G, a biotech company focused on developing therapies for systemic fungal infections. He recently led the company to secure $60.8 million in financing to advance the clinical development of its antifungal agent, olorofim. Nicholson has also negotiated accelerated regulatory approval paths for the company's lead candidate.
Full founder directory · Investor directory · Company funding database · Fundraising library